Journal article
Monoclonal antibody levels and protection from COVID-19
E Stadler, MT Burgess, TE Schlub, SR Khan, KL Chai, ZK McQuilten, EM Wood, MN Polizzotto, SJ Kent, D Cromer, MP Davenport, DS Khoury
Nature Communications | Published : 2023
Abstract
Multiple monoclonal antibodies have been shown to be effective for both prophylaxis and therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled trials assessing the use of monoclonal antibodies (mAb) in preventing symptomatic SARS-CoV-2 infection. We use data on the in vivo concentration of mAb and the associated protection from COVID-19 over time to model the dose-response relationship of mAb for prophylaxis. We estimate that 50% protection from COVID-19 is achieved with a mAb concentration of 96-fold of the in vitro IC50 (95% CI: 32—285). This relationship provides a tool for predicting the prophylactic efficacy of new mAb and against SARS-CoV-2 variants. Finall..
View full abstractGrants
Awarded by Department of Health and Aged Care, Australian Government
Funding Acknowledgements
This work is supported by Australian government Medical Research Future Fund awards GNT2002073 (to M.P.D., S.J.K.), MRF2005544 (to S.J.K., M.P.D.), MRF2005760 (to M.P.D.), MRF2016062 (to S.J.K., M.P.D., D.S.K.) an NHMRC program grant GNT1149990 (S.J.K. and M.P.D.), and the Victorian Government (S.J.K.). NHMRC Investigator grants 1173528 (to D.C.), 1194811 (to Z.K.M.), 1194811 (to E.M.W.), 2016491 (to S.J.K.), and 1173027 (to M.P.D.). K.L.C. is supported by Ph.D. scholarship from the Leukemia Foundation, the Hematology Society of Australia and New Zealand (HSANZ), and Monash University. The Melbourne WHO Collaborating Center for Reference and Research on Influenza is supported by the Australian Government Department of Health.